Navigation Links
Gene signature helps identify risk of relapse in lung cancer patients
Date:4/18/2012

Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

Non-small cell lung cancer is a disease that is often not diagnosed until it has grown and spread throughout the body. Even those patients who are diagnosed early enough to undergo surgical removal of the tumor still have a discouraging 30% rate of relapse.

Researchers hope that identifying which patients have the greatest risk of relapse will allow doctors to focus other treatment strategies, in order to improve their chance of being cured after surgery.

A multidisciplinary team of researchers from Hospital Clinico San Carlos, Madrid, have found a 50-gene predictor that appears to be capable of doing just that. In a study of 84 patients with stage I and II non-small cell lung cancer, who had undergone surgery to remove their tumor, the gene signature accurately predicted which patients were at low risk of relapse.

The researchers analyzed genetic expression in the tumor mass using microarray technology. Following patients for six years, they were able to correlate gene expression patterns with the clinical course of disease, and the risk of relapse.

The Spanish research team's report at the meeting shows that the genes of the predictor were over-expressed in roughly one-third of patients, all of whom had a low risk of relapse. Further analysis showed that these genes were related to the activity of important immune system white blood cells, known as B lymphocytes.

"All of these genes overexpressed in the low-risk group are highly related to B lymphocyte activity," said Dr Florentino Hernando presenting the results at the meeting. "So, the B cell-mediated immune response seems to have a very important role."

The genetic profile identified by the researchers suggests that low-risk patients have an enhanced immune response against the tumor. "Thus, treatments that may interfere with this response such as post-surgical chemotherapy must be reconsidered for the low-risk subgroup," he says.

"One third of patients show an overexpression of an 'immune' genetic signature in their tumor specimens, that is associated with better prognosis," Dr Hernando said. "The fact that this B cell-dependent immune response was associated to the good outcome suggests we should investigate its therapeutic applications in the management of these patients after surgical resection."

Commenting on the study, which he was not involved in, Prof David Carbone from the Vanderbilt-Ingram Cancer Center, member of the IASLC Board, said: "The Spanish group studied tumors from 84 patients with completely resected stage I and II lung cancer for gene RNA expression profiles using 41,000 different probes. Since over half of these patients relapse and die from their cancer in spite of complete resection, there is a pressing need for both defining those patients at the greatest risk of relapse for trials of adjuvant therapy, but also potentially avoiding the toxicity of adjuvant therapy in patients with a low risk of relapse. This is a potentially extremely important classifier, which if independently validated, could be the basis of such a test. It is interesting that the majority of the genes in the classifier are either immune-derived or immunomodulatory, suggesting a potential molecular basis for this observation. It would be interesting to compare the results of this classifier to simple quantitation of lymphocytic infiltration into the resected tumors.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. CIC Teams With Industry Leader iPipeline to Provide Electronic Signature Platform to the Nations Top Insurance Carriers
2. Scientists make strides toward defining genetic signature of Alzheimers disease
3. CIC to Host Webinar Featuring Independent Research Firm: Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology
4. Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer
5. CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda
6. 2009 Signature Genomic Laboratories Travel Award winner announced
7. Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry
8. Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry
9. Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case
10. Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case
11. Parascript Technology Wins Online Signature Verification Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology: